Compare Johnson & Johnson (JNJ) vs Lithium Americas Corp (LAC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Lithium Americas Corp — how do they compare? Johnson & Johnson trades at $261.44 (market cap $618.09B), while Lithium Americas Corp trades at $2.35 (market cap $850.38M). The key difference: Johnson & Johnson is far larger — about 726.8× Lithium Americas Corp's market cap, and Johnson & Johnson pays a 2.09% dividend while Lithium Americas Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and Lithium Americas Corp for 27 Days on average.
| JNJ | LAC | |
|---|---|---|
Market Cap | $618.09B | $850.38M |
Volume | 6,050,983 | 8,804,637 |
Sector | Health | Basic Materials |
52-Week High | $278.43 | $10.05 |
52-Week Low | $186.00 | $2.35 |
Typical Hold Time | 129 Days | 27 Days |
Enterprise Value | $646.37B | $1.19B |
Dividend Yield | 2.09% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $256.48, down 0.76% on the day, with the stock showing mixed technical signals amid a bearish overall trend. The company maintains strong fundamentals with $94.19B in 2025 revenue, 21.48% net income margin, and consistent earnings beats in recent quarters. Recent analyst coverage shows 52.5% buy ratings with a $286.53 consensus price target, while technical indicators point to key support at $248 and resistance at $258.
JNJ presents a compelling long-term investment case with robust profitability, diversified healthcare portfolio, and dividend stability, though near-term headwinds include patent expirations and competitive pressures. The stock's current valuation at 29.75 P/E appears reasonable given strong cash flow generation and pipeline innovation, with upside potential to analyst targets if execution continues.
Lithium Americas (LAC) trades at $2.36, down 2.07% with a bearish technical signal despite recent earnings beats. The company shows negative profitability metrics with ROE at -9.56% and ROA at -3.99%, while maintaining strong analyst support with 7 buy ratings and a $4.00 consensus price target. Recent financing activities and Thacker Pass project development provide growth catalysts amid challenging lithium market conditions.
LAC presents a high-risk opportunity with significant upside potential from its Thacker Pass project execution, though negative cash flow and lithium price volatility create near-term headwinds. The stock trades at a discount to analyst targets but requires successful project ramp-up to justify valuation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Lithium Americas Corp
Lithium Americas is a resource company focused on developing the Thacker Pass project in Nevada, the largest known lithium resource in the US. It aims to become a major supplier for the electric vehicle battery market.
Read more on LAC →
